Journals / Anadolu Kardiyoloji Dergisi / 2011 / Cilt: 11 - Sayı: 4

N-3 çoklu doymamış yağ asitlerinin kullanımı elektriksel kardiyoversiyon sonrası inflamasyon ve atriyal fibrilasyon nüks oranlarını azaltmaz: Prospektif randomize bir çalışma

N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: A prospective randomized study

Pages
305–309
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

High sensitivity C-reactive protein levels at baseline, at day 15 and during AF recurrence were similar between two groups (p > 0.05 for all).Conclusion: N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The purpose of the present prospective randomized study was to evaluate the effects of n-3 polyunsaturated fatty acids on recurrence rates of atrial fibrillation (AF) and inflammation after electrical cardioversion.Methods: Calculation of the number of patients needed was based on the assumption of 20% and 65% chance of maintaining sinus rhythm with amiodarone and with polyunsaturated fatty acids, respectively.
📊
Key Findings & Data:To observe a significant difference with an alpha level of 0.05 and a power of 0.80 it was necessary to include 22 patients in each group.
💡
Conclusion & Impact:High sensitivity C-reactive protein levels at baseline, at day 15 and during AF recurrence were similar between two groups (p > 0.05 for all).Conclusion: N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The purpose of the present prospective randomized study was to evaluate the effects of n-3 polyunsaturated fatty acids on recurrence rates of atrial fibrillation (AF) and inflammation after electrical cardioversion.Methods: Calculation of the number of patients needed was based on the assumption of 20% and 65% chance of maintaining sinus rhythm with amiodarone and with polyunsaturated fatty acids, respectively. To observe a significant difference with an alpha level of 0.05 and a power of 0.80 it was necessary to include 22 patients in each group. A total of 47 patients were randomized to amiodarone (n=24) and amiodarone plus n-3 polyunsaturated fatty acids (n=23) groups before scheduled electrical cardioversion. The end-point was the recurrence of AF during 12-month follow-up. Effect of n-3 polyunsaturated fatty acids on inflammation was evaluated with high sensitivity C-reactive protein level measurements. Statistical analysis was performed using unpaired Student’ t, Mann Whitney U and Chi-square tests. We analyzed the recurrence of AF using the Cox proportional hazards regression model to control for potentially confounding factors. Results: Nine patients in the amiodarone group (37.5%), and 9 patients in the amiodarone plus n-3 polyunsaturated fatty acids group (39.1%) had recurrence of AF during follow-up (p=1). With the Cox proportional model, risk factors for the recurrence of AF were previous electrical cardioversion (HR 10.33, 95% CI 1.74 to 61.10, p=0.01) and high sensitivity C-reactive protein levels (HR 1.07, 95% CI 1.02 to 1.38, p=0.007). High sensitivity C-reactive protein levels at baseline, at day 15 and during AF recurrence were similar between two groups (p > 0.05 for all).Conclusion: N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation.

Özet

Amaç: Bu prospektif randomize çalışmanın amacı, n-3 çoklu doymamış yağ asitlerinin elektriksel kardiyoversiyon sonrası atriyal fibrilasyon (AF) nüksü üzerine olan etkilerini araştırmaktır.Yöntemler: Gerekli hasta sayısı, sinüs ritmi idamesinin amiyodaron grubunda %20, yağ asidi grubunda %65 olacağı tahmin edilerek hesaplandı. Alfa değeri 0.05 ve güç %80 olacak şekilde anlamlı sonuç elde etmek için her bir grupta 22 hastanın gerekli olduğu bulundu. Toplam 47 hasta elektriksel kardiyoversiyon öncesi amiyodaron (n=24) ve amiyodaron+n-3 çoklu doymamış yağ asidi (n=23) gruplarına randomize edildiler. Sonlanım noktası 12 aylık takipte AF nüksü olarak belirlendi. N-3 çoklu doymamış yağ asitlerinin inflamasyon üzerine olan etkisi C-reaktif protein düzeylerinin ölçülmesi ile değerlendirildi. İstatistiksel analiz eşleştirilmemiş Student t-testi, Mann-Whitney U testi Ki-kare testi ile yapıldı. Atriyal fibrilasyon nüksü, potansiyel etkili faktörleri kontrol ederek Cox oransal regresyon modeli ile değerlendirildi. Bulgular: Amiyodaron grubundaki 9 hastada (%37.5) ve amiyodaron+n-3 çoklu doymamış yağ asidi grubundaki 9 hastada (%39.1) nüks gözlendi (p=1). Cox regresyon analizinde, nüks için risk faktörleri önceden elektriksel kardiyoversiyon yapılmış olması (izafi risk 10.33; %95 GA 1.74-61.10; p=0.01) ve yüksek duyarlıklı C-reaktif protein düzeyleri (izafi risk 1.07, %95 GA 1.02-1.38, p=0.007) olarak bulundu. Bazal, 15.günde ve nüks sırasında bakılan çok duyarlı C-reaktif protein düzeyleri iki grupta benzerdi (tümü için p>0.05).Sonuç: Çoklu doymamış yağ asidi kullanılmasının atriyal fibrilasyon nüksü ve inflamasyon üzerine bir etkisi tespit edilmemiştir.

🔖

Cite This Article

ÖZKAN, E., VAROL, E., ERDOĞAN, D., İÇLİ, A., TAYYAR, Ş., UYSAL, B. A., ARSLAN, A., ÖZAYDIN, M., DOĞAN, A., TÜRKER, Y. (2022). N-3 çoklu doymamış yağ asitlerinin kullanımı elektriksel kardiyoversiyon sonrası inflamasyon ve atriyal fibrilasyon nüks oranlarını azaltmaz: Prospektif randomize bir çalışma. Anadolu Kardiyoloji Dergisi, Cilt: 11 - Sayı: 4, 305–309. https://ajindex.com/articles/436537

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-11
  2. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-91
  3. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-4
  4. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455-61
  5. Özaydın M, Doğan A, Varol E, Kapan S, Tüzün N, Peker O, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007; 107: 117-21
  6. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97: 55-60
  7. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-83
  8. Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3: 881-6
  9. Özaydın M, Türker Y, Erdoğan D, Karabacak M, Doğan A, Varol E, et al. The association between previous statin use and development of atrial fibrillation in patients presenting with acute coronary syndrome. Int J Cardiol 2010; 141: 147-50
  10. Özaydın M, Varol E, Aslan SM, Küçüktepe Z, Doğan A, Öztürk M, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97: 1490-3
  11. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92: 1343